03347 TIGERMED
- 36.650
- -0.200-0.54%
TIGERMED News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Intraday Overview | Tech Index rose more than 1%, and TechNet stocks were trending strongly. Bilibili rose more than 6%; Tencent Music rose more than 9% after its performance
Technology Network stocks rose collectively, with Bilibili up more than 6%, Kuaishou and Xiaomi Group up more than 3%; auto stocks improved, Great Wall Motor rose more than 7%, NIO rose nearly 6%, and Zero Sports Auto rose nearly 5%.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The number of repurchased shares cancelled by Tiger Pharmaceuticals (03347) is 7.4697 million shares
Tiger Pharmaceuticals (03347) issued an announcement. The number of repurchased shares cancelled this time was 7.4697 million shares, accounting for before cancellation...
Intraday quick overview | The Science Index rose more than 1% to reach the 4,000 mark; port transport stocks were strong, and COSCO Marine Control rose more than 6%
Water stocks soared across the board. China Water Services rose more than 9%, Beijing Water Group rose more than 8%; high-speed rail infrastructure stocks collectively rallied, CRRC rose more than 9%, and Times Electric rose nearly 7%.
CRO concept stocks opened and surged. Baihua Pharmaceuticals rose and stopped. Wanbang Pharmaceuticals rose more than 17%, Pharmaceutical Kangde rose more than 8%, and Kanglong Chemical, Gloria Ying, and Tiger Pharmaceuticals all opened higher.
CRO concept stocks opened and surged. Baihua Pharmaceuticals rose and stopped. Wanbang Pharmaceuticals rose more than 17%, Pharmaceutical Kangde rose more than 8%, and Kanglong Chemical, Gloria Ying, and Tiger Pharmaceuticals all opened higher.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | May 13
According to data disclosed on May 10, 2024, Beijing Finance International (01468.HK), Hang Seng China Enterprise (02828.HK), and Southern Hang Seng Technology (03033.HK) Hong Kong Stock Connect held the largest share value added, increasing by 3.52%, 1.10%, and 0.80% respectively; Marco Digital Technology (01942.HK), Tiger Pharmaceuticals (03347.HK), and Huadian Power (01071.HK) Hong Kong Stock Connect shares decreased the most, decreasing by -0.48% and -0.44%, respectively, -0.44%.
Strong inflow of foreign capital is another trend vane: Middle Eastern tycoons increase their presence in China, and multinational sovereign wealth funds continue to lay out A-shares
① The Abu Dhabi Investment Authority and the Kuwait Investment Authority held a large number of A-share listed companies in the first quarter; ② the Middle East Sovereign Fund also stepped up research on A-shares ③ Other overseas sovereign wealth funds are increasing their layout in the Chinese market.
Tiger Pharmaceuticals (300347) In-depth Research Report: Local clinical CRO leaders are expected to fully benefit from the industry's rise in volume and price
Tiger Pharmaceuticals has strong competitiveness in comprehensive development: 1. Covers the entire R&D industry chain, provides integrated R&D solutions, and has rich project experience; 2. It has simultaneous global operation and management capabilities, and a wide cooperative network with global research institutions; 3. Excellent
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Zhitong Hong Kong Stock Exchange Unravels | A-shares make up gains and continues to boost Hong Kong stocks need to be wary of attacking Rafah
The current problem with Hong Kong stocks is nothing more than a matter of profit digestion, but under the stimulus of the money-making effect, the entry of incremental capital is expected to form a hedge
Hong Kong stocks closed (05.06) | The Hang Seng Index closed up 0.55% to reap the Shilianyang CRO concept, strong high-speed rail infrastructure stocks, and domestic housing stocks fell across the board
The US non-farm payrolls data for April fell short of expectations, and expectations of market interest rate cuts rebounded somewhat. Hong Kong stocks bottomed out and rebounded today. The three major indices all turned red. The Hang Seng Index successfully reaped 10 consecutive days, and the Hengke Index also reached the 4,000 point mark.
Hong Kong Stock Afternoon Review | The three major indices fluctuated slightly, pharmaceutical stocks strengthened against the market, and Pharmaceutical Biotech rose more than 5%
Most Technet stocks weakened, with Kuaishou falling nearly 2%, Meituan, Xiaomi, and Bilibili falling more than 1%; travel and tourism stocks generally rising, with Ctrip Group rising nearly 3%, Hong Kong China Travel up more than 2%, and Tongcheng Travel up more than 1%.
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
Changes in Hong Kong stocks | Yao Ming Biotech rose more than 7% to lead CRO concept stocks. The Federal Reserve may still cut interest rates during the year, and overseas demand is expected to resume
On May 6, CRO concept stocks had the highest gains in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 6.82% to HK$36.8; Pharmaceutical Biotech (02269) rose 5.87% to HK$36.45; Kanglong Chemical (03759) rose 4.92% to HK$10.44; and Pharmaceuticals Kangde (02359) rose 3.14% to HK$37.75.
Hong Kong CXO concept stocks fluctuated higher, and Pharmaceutical Biotech rose more than 8%
Gelonghui, May 6 | Yao Ming Biotech rose more than 8%, Tiger Pharmaceuticals and Kanglong Chemical rose more than 5%, while Pharmaceutical Kangde and Kingsry Biotech had the highest gains.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Analysis
Price Target
No Data
